Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation

(2011) Jane M Valentine et al.   BMC CANCER

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

(2011) Yuan Yuan et al.   Journal of Hematology & Oncology

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

(2011) M H Aziz et al.   ONCOGENE

p53 Transactivation and the Impact of Mutations, Cofactors and Small Molecules Using a Simplified Yeast-Based Screening System

(2011) Virginia Andreotti et al.   PLoS One

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

(2011) M Michaelis et al.   Cell Death & Disease

Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1

(2010) Ramesh M. Ray et al.   APOPTOSIS

Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA

(2010) Carolyn Y. Zhao et al.   CELL CYCLE

Reactivation of p53: from peptides to small molecules

(2010) Christopher J. Brown et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

DNA damage response to the Mdm2 inhibitor Nutlin-3

(2009) Rajeev Verma et al.   BIOCHEMICAL PHARMACOLOGY

Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines

(2009) Martin Michaelis et al.   BIOCHEMICAL PHARMACOLOGY

Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1  and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia

(2009) J. Yang et al.   MOLECULAR AND CELLULAR BIOLOGY

Transient Nutlin-3a Treatment Promotes Endoreduplication and the Generation of Therapy-Resistant Tetraploid Cells

(2008) H. Shen et al.   CANCER RESEARCH